Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2015.4707 mmr-13-02-1746 Articles Differential gene expression analysis and network construction of recurrent cardiovascular events LIAOJIANGQUAN12* CHENZHONG12* HEQINGHONG1* LIUYONGMEI1 WANGJIE1 Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China Graduate School, Beijing University of Chinese Medicine, Beijing 100059, P.R. China Correspondence to: Professor Jie Wang, Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, 5 Beixiange, Xicheng, Beijing 100053, P.R. China, E-mail: wangjie0103@126.com

Contributed equally

 02 2016 22 12 2015 13 2 1746 1764 10 01 2015 02 11 2015 Copyright © 2016, Spandidos Publications 2016

Recurrent cardiovascular events are vital to the prevention and treatment strategies in patients who have experienced primary cardiovascular events. However, the susceptibility of recurrent cardiovascular events varies among patients. Personalized treatment and prognosis prediction are urged. Microarray profiling of samples from patients with acute myocardial infarction (AMI), with or without recurrent cardiovascular events, were obtained from the Gene Expression Omnibus database. Bioinformatics analysis, including Gene Oncology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG), were used to identify genes and pathways specifically associated with recurrent cardiovascular events. A protein-protein interaction (PPI) network was constructed and visualized. A total of 1,329 genes were differentially expressed in the two group samples. Among them, 1,023 differentially expressed genes (DEGs; 76.98%) were upregulated in the recurrent cardiovascular events group and 306 DEGs (23.02%) were downregulated. Significantly enriched GO terms for molecular functions were nucleotide binding and nucleic acid binding, for biological processes were signal transduction and regulation of transcription (DNA-dependent), and for cellular component were cytoplasm and nucleus. The most significant pathway in our KEGG analysis was Pathways in cancer (P=0.000336681), and regulation of actin cytoskeleton was also significantly enriched (P=0.00165229). In the PPI network, the significant hub nodes were GNG4, MAPK8, PIK3R2, EP300, CREB1 and PIK3CB. The present study demonstrated the underlying molecular differences between patients with AMI, with and without recurrent cardiovascular events, including DEGs, their biological function, signaling pathways and key genes in the PPI network. With the use of bioinformatics and genomics these findings can be used to investigate the pathological mechanism, and improve the prevention and treatment of recurrent cardiovascular events.

 recurrent cardiovascular events microarray profile differential expressed genes protein-protein interaction network bioinformatics Introduction

With the significant advances in medication, reperfusion therapy, cardiac rehabilitation and organ transplantation, cardiovascular disease remains one of the major causes of mortality worldwide (1). Evaluation of cardiovascular disease based on risk factors is important in the clinical prevention and treatment of cardiovascular disease, which may alter the risk stratification and guide the treatment and prognosis (2,3). More and more indexes are included in the risk stratification as clinical and experimental research develops, including brain natriuretic peptide, C reactive protein and blood homocysteine. However, the prediction of cardiovascular disease is not so satisfying (4), particularly in personalized prevention and treatment. Sensitivity of risk factors varies in different individuals, and clinical doctors must be aware of this and objective to the current risk factors and stratification (5). More superior and systematic algorithms for stratification remain to be elucidated (6).

The evaluation and stratification of cardiovascular diseases depend more on primary cardiovascular events, which elevate the stratification and enhance the treatment once they occur. However, recurrent cardiovascular events are also vital, which indicate that the current intervention is not marked enough to prevent disease progression. Although patients receive standard treatment based on the risk factors stratification, recurrent cardiovascular events still occur, which indicates that certain individuals are more prone to recurrent cardiovascular events. These patients may require more aggressive therapies, involving susceptibility screening and personalized treatment (7). With the development and application of clinical genomics technology and bioinformatics, novel biomarkers are used in the diagnosis and prognosis of cardiovascular disease (8,9). Previous research revealed that the expression of different genes varies in different stages of cardiovascular diseases, and these genes are involved in the pathological process, and may even predict the cardiovascular events (10). With the help of genomics and bioinformatics, patient susceptibility to recurrent cardiovascular events may be screened out, and personalized treatment can be made. This may reduce the recurrence of cardiovascular events and improve the prognosis. The present study used genomics and bioinformatics technology, and associated software to analyze the differentially expressed genes (DEGs) associated with recurrent cardiovascular events. The present study also aimed to identify the key genes in the pathological process and provide alternative guidance in the preventions, and personalized treatment of recurrent cardiovascular events.

 Materials and methods Microarray data and clinical characteristics

The microarray dataset, GSE48060 with GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array platform, was obtained from the Gene Expression Omnibus (GEO) database (11). The data samples were peripheral blood samples collected from patients with acute myocardial infarction (AMI) 48 h within the primary AMI. All 27 samples were divided into two groups, according to the recurrence of cardiovascular events in the 18 month follow-up. A total of five patients exhibited recurrent cardiovascular events and 22 did not. The definition of recurrent cardiovascular events is recurrent myocardial infarction, re-vascularization, evidence of restenosis, hospitalization for unstable angina or heart failure, cardiovascular mortality, stroke or transient ischemic attack, or amputation due to peripheral vascular disease.

 Raw data processing

All 27 sample files were downloaded from the GEO database and were reanalyzed using R software (version 3.1.1; http://www.r-project.org/). The Affy package was applied to read the probe set data from the CEL files (12). Robust Multiarray Averaging was used to normalize the original data. Following standardization, a total of 54,675 probe set IDs' expression levels in different samples were obtained.

 Screening and annotation of the DEGs

The limma package in the R software was used to compare the expression levels of the probe sets between the two groups (13). The threshold was set as P<0.05 or a fold change >1.5. The annotate package was used to annotate the DEGs.

 Enrichment analysis of DEGs

GeneCodis online tools (http://genecodis2.dacya.ucm.es/) were used to annotate and analyze the DEGs (14,15). The annotation and analysis were predominantly focussed on the molecular function, the biological process and the cellular component of Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The threshold was set as P<0.05.

 Protein-protein interaction (PPI) network analysis

Cytoscape (version 3.1.1; The Cytoscape Consortium, San Diego, CA, USA) and reactome plugin were applied to analyze the DEGs (16), and to construct and visualize the PPI network. Further analysis of the key nodes in the PPI network were processed.

 Results Clinical characteristics of the two group samples

According to Suresh et al (11), the clinical characteristics between the recurrence and no recurrence groups, including age, sex, body mass index, cardiovascular risk factor score, lipid profile and severity of AMI, were similar with the exception of the usage of beta-blockers. The clinical characteristic details are listed in Table I.

 Recurrent cardiovascular event-associated DEGs

By comparing the two group samples of with or without recurrent cardiovascular events in the 18 month follow-up following primary AMI, 1,329 genes (2.43% of total probe set) were identified to be differentially expressed and annotatable. A total of 1,023 DEGs (76.98%) were upregulated and 306 DEGs (23.02%) were downregulated in the recurrent cardiovascular events group. The top 10 markedly up or downregulated genes with a fold change >1.5 are listed in Tables II and III, respectively.

 Significant GO enrichment

To gain insights into the biological roles of the DEGs in recurrent cardiovascular events, a GO categories enrichment analysis was performed using GeneCoDis. GO categories are predominantly in three groups: Biological process, cellular component and molecular function. The significantly enriched GO terms for molecular functions were nucleotide binding (GO:0000166, P=8.24−19) and nucleic acid binding (GO:0003676, P=1.94−07), for biological processes were signal transduction (GO:0007165, P=5.26−08) and regulation of transcription, DNA-dependent (GO:0006355, P=9.19−06), and for cellular component were cytoplasm (GO:0005737, P=8.98−25) and nucleus (GO:0005634, P=1.91−23; Fig. 1).

 Significant pathways

KEGG pathway enrichment analysis was performed to further evaluate the biological significance of the DEGs. The most significant pathway in our KEGG analysis was Pathways in cancer (P=0.000336681). Furthermore, Melanoma (P=0.000336681) and Regulation of actin cytoskeleton (P=0.00165229) were revealed to be highly enriched. The top 15 enriched KEGG pathways of the DEGs are listed in Table IV.

 PPI network construction and visualization

By analyzing the identified 1,329 DEGs using Cytoscape and the reactome plugin, 330 genes (node) and 796 gene-gene interactions (edge) were identified. The result was visualized in Cytoscape and the majority of the nodes were located within one network. To modify the PPI network, the sizes of the nodes were set according to their interaction density with the other nodes. The node color of the upregulated DEGs were made red and those downregulated were made blue (Fig. 2). The more that one gene interacts with the other genes, the larger the node was and the more central this gene occurs within the network. The genes, GNG4, MAPK8 and PIK3R2 were the three predominantly upregulated genes, while EP300, CREB1 and PIK3CB were the predominantly downregulated genes in the PPI network. The details of the nodes are listed in Table V.

 Discussion

Cardiovascular events are important in the prevention and treatment of cardiovascular diseases. When it occurs in patients with risk factors, the heart function must be re-evaluated, and the prevention and treatment strategy must be adjusted. For patients who had experienced cardiovascular events, the prevention and treatment strategies are not uniform between different regions and hospitals. There are divergences between different area and different grades of hospitals (17), conservative and aggressive strategies are being used, not to mention the circumstances vary among individuals, efficient and effective personalized evaluation and treatment are urged (18). Previous research has revealed that whole-genome sequencing can be used in cardiovascular disease risk-prediction algorithms, to more accurately forecast whether patients will develop disease (19). However, there remains a lack of research about microarray profiling in recurrent cardiovascular events. The present study performed a microarray profiling of peripheral blood samples from patients with AMI, downloaded from the GEO database, to focus on the DEGs of those with or without recurrent cardiovascular events 18 months following AMI.

R is an integrated suite of software facilities for data manipulation, calculation and graphical display. Using R software and certain packages, the present study identified the DEGs between patients with AMI, with or without recurrent cardiovascular disease. A total of 1,329 genes were identified and 1,023 were upregulated in recurrent group compared with the no recurrent group, while 306 of them were downregulated. The genes with the most significant P-value and fold change >1.5 in the up and downregulated DEGs are listed in Tables II and III. Among them, TUBB1 (tubulin β1, class VI; P=0.00544; fold change=1.56) encodes a member of the β tubulin protein family, and this protein is specifically expressed in platelets and megakaryocytes, and may be involved in proplatelet production and platelet release. Previous research revealed that the prevalence of TUBB1 was higher among healthy individuals compared with patients with cardiovascular disease (20). This may be associated with the TUBB1 function of suppressing microtubule dynamics, fragmenting microtubules and inhibiting cell division (21). Although there is little previous research about other significant genes involved in cardiovascular diseases, the method in the present study may be the initial and alternative way to explore the pathological mechanism of recurrent cardiovascular events.

To further investigate the roles of the DEGs identified in the pathological mechanism of recurrent cardiovascular events, GO enrichment analysis and KEGG pathway analysis was used. GO is widely used as the tool for the organization and functional annotation of molecular aspect (22). It was revealed that the significantly enriched GO terms for molecular functions were nucleotide binding and nucleic acid binding, for biological processes were signal transduction and regulation of transcription (DNA-dependent), and for cellular component were cytoplasm and nucleus. The GO terms mentioned above are basic and vital to the biological and pathological process. Fibroblast growth factor receptor signaling pathway (GO:0008543; P=0.00151494), blood coagulation (GO:0007596; P=0.00166723) and cell adhesion (GO:0007155; P=00170222) were also significantly enriched in GO biological process. Ronca et al (23) reported that fibroblast growth factor receptor-1 gene knockout impairs cardiac and haematopoietic development in murine embryonic stem cells, and the fibroblast growth factor receptor is required for cardiomyocyte differentiation. Yukawa et al (24) demonstrated that impaired fibroblast growth factor receptor gene would suppress the growth of vascular smooth muscle. As for blood coagulation and cell adhesion, which are associated with the formation and breaking off of thrombosis, they are important in both primary and recurrent cardiovascular events.

In KEGG pathway analysis, regulation of actin cytoskeleton is significantly enriched. Actin cytoskeleton is involved in the inward remodeling process associated with cytoskeletal modifications. It is also involved in reducing the passive diameter of resistance vessels, which are the vascular components of the circulatory system, and exert a preponderant role in the regulation of blood flow and the modulation of blood pressure (25). Therefore, the regulation of actin cytoskeleton may have profound consequences on the incidence of cardiovascular events.

The results from PPI network analysis of the top 10 up and downregulated DEGs revealed the significant nodes, including GNG4, MAPK8, PIK3R2, EP300, CREB1 and PIK3CB. MAPK8 is one member of the MAPK family, which has vast implications in signaling and crosstalk with other signaling networks. The MAPK signal pathway is highly associated with mitochondria, the power houses of the cell, which provide >80% of ATP for normal cardiomyocyte function and have a crucial role in cell death (26). EP300 is the node with the most interactions with other nodes in the PPI network, and previous research revealed that it is associated with arterial stiffness prior to hypertension, increased pulse pressure, and structural vessel wall changes (27). CREB1, also termed CREB, phosphorylation induced by the prostacyclin/IP pathway may suppress cardiac fibrosis, which is a consequence of numerous cardiovascular diseases, and contributes to impaired ventricular function (28). The PPI results suggested that MAPK8, EP300 and CREB1 may be important in the development of recurrent cardiovascular events.

The results from the present study suggested that DEGs exist between patients with AMI, with and without recurrent cardiovascular events. These genes are involved in different GO enrichment terms and signaling pathways, from which insights into the pathological processes of recurrent events can be obtained. Several genes, including TUBB1, GNG4, MAPK8, PIK3R2, EP300 and CREB1, with or without previous research, may provide potential candidates for distinguishing the susceptibility to recurrent cardiovascular events in the future. Therefore, the present research may provide important references for the prevention and treatment strategies in patients with primary cardiovascular events. Nevertheless, the genes and the associated GO enrichment terms and pathways identified here require further investigation and confirmation.

In conclusion, the present study revealed the underlying molecular differences between patients with AMI, with and without recurrent cardiovascular events, including DEGs, their biological function, signaling pathways and key genes in the PPI network, which may contribute to the prevention of recurrent events and personalized treatment for primary cardiovascular events. Further functional studies may provide additional insights into the role of the DEGs in the pathological process of recurrent cardiovascular events.

 Acknowledgments

The present research was supported by a grant from the National Natural Science Foundation of China (no. 81173166).

 References GoASMozaffarianDRogerVLBenjaminEJBerryJDBlahaMJDaiSFordESFoxCSFrancoSHeart disease and stroke statistics-2014 update: A report from the American heart associationCirculation129e28e292201410.1161/01.cir.0000441139.02102.80 GoffDCJrLloyd-JonesDMBennettGCoadySD'AgostinoRBGibbonsRGreenlandPLacklandDTLevyDO'DonnellCJ2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelinesCirculation12925 Suppl 2S49S73201410.1161/01.cir.0000437741.48606.98 PerkJDe BackerGGohlkeHGrahamIReinerZVerschurenMAlbusCBenlianPBoysenGCifkovaREuropean Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)Eur Heart J3316351701201210.1093/eurheartj/ehs09222555213 CeškaRŠtulcTImplementation of cardiovascular disease prevention guidelines into clinical practice: An unmet challenge?Curr Pharm Des2111801184201510.2174/1381612820666141013152521 van StaaTPGullifordMNgESGoldacreBSmeethLPrediction of cardiovascular risk using framingham, ASSIGN and QRISK2: How well do they predict individual rather than population risk?PLoS One9e106455201410.1371/journal.pone.0106455252714174182667 TaljaardMTunaMBennettCPerezRRosellaLTuJVSanmartinCHennessyDTanuseputroPLebenbaumMManuelDGCardiovascular disease population risk tool (CVDPoRT): Predictive algorithm for assessing CVD risk in the community setting. A study protocolBMJ Open10e006701201410.1136/bmjopen-2014-006701 CuiJForbesAKirbyAMarschnerISimesJHuntDWestMTonkinASemi-parametric risk prediction models for recurrent cardiovascular events in the LIPID studyBMC Med Res Methodol1027201010.1186/1471-2288-10-27203564092856584 XuFTengXYuanXSunJWuHZhengZTangYHuSLCK: A new biomarker candidate for the early diagnosis of acute myocardial infarctionMol Biol Rep4180478053201410.1007/s11033-014-3702-825209966 DuanLXiongXLiuYWangJmiRNA-1: Functional roles and dysregulation in heart diseaseMol Biosyst1027752782201410.1039/C4MB00338A25177824 TikkanenEHavulinnaASPalotieASalomaaVRipattiSGenetic risk prediction and a 2-stage risk screening strategy for coronary heart diseaseArterioscler Thromb Vasc Biol3322612266201310.1161/ATVBAHA.112.301120235994444210840 SureshRLiXChiriacAGoelKTerzicAPerez-TerzicCNelsonTJTranscriptome from circulating cells suggests dysregulated pathways associated with long-term recurrent events following first-time myocardial infarctionJ Mol Cell Cardiol741321201410.1016/j.yjmcc.2014.04.017248017074115027 GautierLCopeLBolstadBMIrizarryRAAffy-analysis of Affymetrix GeneChip data at the probe levelBioinformatics20307315200410.1093/bioinformatics/btg40514960456 SmythGKMichaudJScottHSUse of within-array replicate spots for assessing differential expression in microarray experimentsBioinformatics2120672075200510.1093/bioinformatics/bti27015657102 Nogales-CadenasRCarmona-SaezPVazquezMVicenteCYangXTiradoFCarazoJMPascual-MontanoAGeneCodis: Interpreting gene lists through enrichment analysis and integration of diverse biological informationNucleic Acids Res37W317W322200910.1093/nar/gkp416194653872703901 Carmona-SaezPChagoyenMTiradoFCarazoJMPascual-MontanoAGENECODIS: A web-based tool for finding significant concurrent annotations in gene listsGenome Biol8R3200710.1186/gb-2007-8-1-r3172041541839127 SaitoRSmootMEOnoKRuscheinskiJWangPLLotiaSPicoARBaderGDIdekerTA travel guide to cytoscape pluginsNat Methods910691076201210.1038/nmeth.2212231321183649846 MortensenMBFalkEReal-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarctionBMJ Open4e005991201410.1136/bmjopen-2014-005991253262114201996 MontecuccoFCarboneFDiniFLFiuzaMPintoFJMartelliAPalomboDSambucetiGMachFDe CaterinaRImplementation strategies of systems medicine in clinical research and home care for cardiovascular disease patientsEur J Intern Med25785794201410.1016/j.ejim.2014.09.01525283057 MusunuruKPersonalized genomes and cardiovascular diseaseCold Spring Harb Perspect Med5a014068201410.1101/cshperspect.a01406825256177 FresonKDe VosRWittevrongelCThysCDefoorJVanheesLVermylenJPeerlinckKVan GeetCThe TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structureBlood10623562362200510.1182/blood-2005-02-072315956286 YangHGangulyAYinSCabralFMegakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell divisionCytoskeleton (Hoboken)68175187201110.1002/cm.20503 LoveringRCCamonEBBlakeJADiehlADAccess to immunology through the gene ontologyImmunology125154160200810.1111/j.1365-2567.2008.02940.x187989192561138 RoncaRGualandiLCresciniECalzaSPrestaMDell'EraPFibroblast growth factor receptor-1 phosphorylation requirement for cardiomyocyte differentiation in murine embryonic stem cellsJ Cell Mol Med1314891498200910.1111/j.1582-4934.2009.00805.x195490743828861 YukawaHMiyatakeSISaikiMTakahashiJCMimaTUenoHNagataIKikuchiHHashimotoNIn vitro growth suppression of vascular smooth muscle cells using adenovirus-mediated gene transfer of a truncated form of fibroblast growth factor receptorAtherosclerosis141125132199810.1016/S0021-9150(98)00162-29863545 Castorena-GonzalezJAStaiculescuMCFooteCMartinez-LemusLAMechanisms of the inward remodeling process in resistance vessels: Is the actin cytoskeleton involved?Microcirculation21219229201410.1111/micc.12105246355093988214 JavadovSJangSAgostiniBCrosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: Therapeutic perspectivesPharmacol Ther144202225201410.1016/j.pharmthera.2014.05.013249247004185221 HerreraVLDecanoJLGiordanoNMoranAMRuiz-OpazoNAortic and carotid arterial stiffness and epigenetic regulator gene expression changes precede blood pressure rise in stroke-prone Dahl salt-sensitive hypertensive ratsPLoS One9e107888201410.1371/journal.pone.0107888252292454168262 ChanECDustingGJGuoNPeshavariyaHMTaylorCJDilleyRNarumiyaSJiangFProstacyclin receptor suppresses cardiac fibrosis: Role of CREB phosphorylationJ Mol Cell Cardiol49176185201010.1016/j.yjmcc.2010.04.00620403362

GO enrichment. (A) Molecular functions, (B) biological processes and (C) cellular components for the differentially expressed genes. The order of GO enrichment terms were sorted by P-value. GO, gene ontology.

Protein-protein interaction network visualization of differentially expressed genes. The nodes in red represent the upregulated genes and those in blue represent the downregulated genes. The larger size nodes interact more with other nodes. The type of edges represents the interaction between the nodes, → to indicate activating/catalyzing, -| to indicate inhibition, - for functional interactions extracted from complexes or inputs and — for predicted functional interactions.

Baseline clinical characteristics of AMI patients with or without recurrent events following primary AMI, who underwent whole-genome blood gene expression microarray analysis.

Variable Event (n=5) No event (n=22) P-value
Age, years 51 (41–53) 56.5 (48–65) 0.110
Gender, male, n (%) 3 (60) 13 (59) 0.972
Body mass index, kg/m2 36.5 (25.0–46.5) 31.5 (22.9–48.4) 0.140
Cardiovascular risk factor score 5 (4–6) 4 (1–6) 0.266
Cardiovascular history, n (%)
 Arterial hypertension, n (%) 5 (100) 13 (59) 0.080
 Smoking, n (%) 2 (40) 16 (73) 0.161
 Diabetes mellitus, n (%) 0 (0) 3 (14) 0.381
 Family history of coronary artery disease, n (%) 5 (100) 12 (55) 0.057
Lipid profile, mg/dl
 Total cholesterol, mg/dl 128 (110–219) 191 (126–325 0.190
 Low density lipoprotein cholesterol, mg/dl 65 (41–152) 115 (70–254) 0.169
 HDL cholesterol, mg/dl 31 (25–47) 38 (25–72) 0.165
Medication
 Statin therapy, n (%) 3 (60) 7 (33) 0.271
 Aspirin, n (%) 4 (80) 12 (55) 0.296
 ACE inhibitor, n (%) 1 (20) 4 (19) 0.961
 Beta blocker, n (%) 4 (80) 5 (22) 0.014
Severity of AMI
 Ejection fraction, % 55 (43–65) 57 (35–71) 0.240
 Troponin, ng/ml 2.24 (0.11–9.51) 0.47 (0.04–16.43) 0.142
 STEMI, n (%) 2 (40) 7 (32) 0.726

AMI, acute myocardial infarction.

Top 10 upregulated genes.

Gene Fold change Mean of intensity
P-value Official gene name
Recurrence No recurrence
LRRC18 1.58 21.38 13.50 1.14−04 Leucine rich repeat containing 18
IRAK1BP1 1.77 90.64 51.19 6.19−04 Interleukin-1 receptor-associated kinase 1 binding protein 1
MGAT4A 1.57 385.69 245.89 6.00−03 Mannosyl (α-1,3-)-glycoprotein β-1, 4-N-acetylglucosaminyltransferase, isozyme A
BZW2 1.74 921.80 529.93 9.33−03 Basic leucine zipper and W2 domains 2
LOC152586 1.64 19.38 11.84 1.25−02 MGAT4 family, member D
ADTRP 1.78 272.08 153.19 1.46−02 Androgen-dependent TFPI-regulating protein
SMC1B 1.78 24.76 13.94 2.02−02 Structural maintenance of chr 1B
LOC283788 1.53 147.03 96.39 2.39−02 Hypothetical protein LOC283788
CLDN12 1.52 37.24 24.58 2.56−02 Claudin 12
LEF1-AS1 1.79 74.60 41.72 3.32−02 LEF1 antisense RNA 1

Genes with a fold change >1.5 are shown. Data are sorted by P-value.

Top 10 downregulated genes.

Gene Fold change Mean of intensity
P-value Official gene name
Recurrence No recurrence
HIST1H2AC 1.57 2086.82 3273.74 2.50−03 Histone cluster 1, H2ac
NEXN 1.65 199.36 329.40 4.46−03 Nexilin (F actin binding protein)
SIRPB2 1.76 102.91 181.12 4.77−03 Signal-regulatory protein β2
TUBB1 1.56 462.45 719.52 5.44−03 Tubulin β1
HIST1H2BD 1.56 254.17 397.28 5.81−03 Histone cluster 1, H2bd
TSPAN2 1.76 142.35 250.81 6.02−03 Tetraspanin 2
GUCY1A3 1.55 12.14 18.80 6.57−03 Guanylate cyclase 1, soluble, α 3
FAR2 1.77 129.96 230.38 7.84−03 Fatty acyl CoA reductase 2
STON2 1.66 91.55 151.83 9.06−03 Nexilin (F actin binding protein)
DLEU2 1.62 63.13 102.52 1.11−02 Deleted in lymphocytic leukemia 2

Genes with a fold change >1.5 are shown. Data are sorted by P-value.

Top 15 enriched KEGG pathways of differentially expressed genes.

KEGG ID KEGG pathway Gene no. P-value
hsa05200 Pathways in cancer 12 3.37−04
hsa05218 Melanoma 12 3.37−04
hsa04810 Regulation of actin cytoskeleton 9 1.65−03
hsa05215 Prostate cancer 11 1.77−03
hsa04010 MAPK signaling pathway 23 2.04−03
hsa04120 Ubiquitin mediated proteolysis 14 6.34−03
hsa04660 T cell receptor signaling pathway 4 7.80−03
hsa05340 Primary immunodeficiency 4 7.80−03
hsa05214 Glioma 7 8.34−03
hsa05222 Small cell lung cancer 10 9.31−03
hsa04510 Focal adhesion 6 1.68−02
hsa04144 Endocytosis 16 1.98−02
hsa03030 DNA replication 4 2.07−02
hsa03430 Mismatch repair 4 2.07−02
hsa04115 p53 signaling pathway 8 2.28−02

KEGG, Kyoto Encyclopedia of Genes and Genomes.

Network features of differentially expressed genes included in protein-protein interaction network sorted by degree.

Gene Description Betweenness centrality Degree Indegree Outdegree Regulation
EP300 E1A binding protein p300 0.03886829 81 25 56 Down
GNG4 Guanine nucleotide binding protein (G protein), γ 4 0.00246082 26 9 17 Up
MAPK8 Mitogen-activated protein kinase 8 0.00373044 22 12 10 Up
PIK3R2 Phosphoinositide-3-kinase, regulatory subunit 2 (p85 β) 0.00275468 22 17 5 Up
E2F1 E2F transcription factor 1 0.00881333 21 5 16 Up
CREB1 CAMP responsive element binding protein 1 0.0020355 18 4 14 Down
PIK3CB Phosphoinositide-3-kinase, catalytic, β polypeptide 0.00123254 18 13 5 Down
HIST1H2BC Histone cluster 1, H2bc 0.00045679 18 8 10 Down
HIST1H2BK Histone cluster 1, H2bk 0.00044752 18 11 7 Down
HIST1H2BJ Histone cluster 1, H2bj 0.00044752 18 10 8 Down
HIST2H2BE Histone cluster 2, H2be 0.00084908 18 11 7 Down
HIST1H2BD Histone cluster 1, H2bd 0.00039501 17 8 9 Down
ANAPC10 Anaphase promoting complex subunit 10 0 17 0 17 Up
AR Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; kennedy disease) 0 16 0 16 Up
CDK4 Cyclin-dependent kinase 4 0.00042396 16 1 15 Up
HIST1H2AC Histone cluster 1, H2ac 0.000341 16 5 11 Down
H2BFS H2B histone family, member S 0.00003574 16 4 12 Down
SMURF1 SMAD specific E3 ubiquitin protein ligase 1 0.00112437 15 11 4 Up
PABPC1 Poly (A) binding protein, cytoplasmic 1 0.00046983 14 4 10 Up
RING1 Ring finger protein 1 0.00051894 14 13 1 Up
MAX MYC associated factor X 0.00190278 13 5 8 Down
FLT1 Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) 0.00358728 13 7 6 Up
SKP2 S-phase kinase-associated protein 2 (p45) 0.0016332 13 8 5 Up
CBX8 Chromobox homolog 8 (Pc class homolog, Drosophila) 0.00101008 12 1 11 Up
TAF1 TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250 kDa 0.00086181 12 11 1 Up
BCL3 B-cell CLL/lymphoma 3 0.00123249 12 1 11 Up
GNA11 Guanine nucleotide binding protein (G protein), α 11 (Gq class) 0.00031838 12 3 9 Up
GNAQ Guanine nucleotide binding protein (G protein), q polypeptide 0.00064179 12 6 6 Down
PMF1 Polyamine-modulated factor 1 0.00076915 11 9 2 Up
CBX2 Chromobox homolog 2 (Pc class homolog, drosophila) 0 11 0 11 Up
HUWE1 HECT, UBA and WWE domain containing 1 0.00050967 11 4 7 Up
KDM6B Lysine (K)-specific demethylase 6B 0 11 9 2 Down
UBE3A Ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome) 0.00000927 11 10 1 Up
FGFR1 Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) 0.00350998 11 6 5 Up
PHC1 Polyhomeotic homolog 1 (Drosophila) 0 11 10 1 Up
SMAD9 SMAD family member 9 0.0020102 11 8 3 Down
CKAP5 Cytoskeleton associated protein 5 0.000139 11 2 9 Up
NOTCH1 Notch homolog 1, translocation-associated (Drosophila) 0.00167253 11 6 5 Down
FBXO3 F-box protein 3 0 10 2 8 Up
UBE2Q1 Ubiquitin-conjugating enzyme E2Q (putative) 1 0.00000927 10 8 2 Up
KIF2A Kinesin heavy chain member 2A 0.00010193 10 4 6 Down
UBE2W Ubiquitin-conjugating enzyme E2W (putative) 0.00000927 10 8 2 Down
HECTD3 HECT domain containing 3 0 10 3 7 Up
ASB3 Ankyrin repeat and SOCS box-containing 3 0 10 1 9 Up
EGF Epidermal growth factor (β-urogastrone) 0.00189305 10 2 8 Down
GATA2 GATA binding protein 2 0.00200163 10 4 6 Down
RPSA Ribosomal protein SA 0.00015167 10 7 3 Up
VPRBP Vpr (HIV-1) binding protein 0 10 10 0 Up
CLIP1 CAP-GLY domain containing linker protein 1 0.0000556 10 2 8 Up
RNPS1 RNA binding protein S1, serine-rich domain 0.00017607 10 2 8 Up
GPC3 Glypican 3 0.00296725 9 3 6 Up
EIF3B Eukaryotic translation initiation factor 3, subunit B 0 9 0 9 Up
RPS28 Ribosomal protein S28 0.00004973 9 6 3 Up
RPS15A Ribosomal protein S15a 0.00004973 9 5 4 Up
PML Promyelocytic leukemia 0.00137496 9 6 3 Up
ITGA9 Integrin, α 9 0.00008649 9 6 3 Up
JUND Jun D proto-oncogene 0.00140147 9 4 5 Up
NSL1 NSL1, MIND kinetochore complex component, homolog (S. cerevisiae) 0 8 6 2 Up
RHOD Ras homolog gene family, member D 0.00038457 8 7 1 Up
HSPG2 Heparan sulfate proteoglycan 2 0.00096904 8 5 3 Up
SPC24 SPC24, NDC80 kinetochore complex component, homolog (S. cerevisiae) 0 8 8 0 Up
CD4 CD4 molecule 0.00166231 8 2 6 Up
NCOA1 Nuclear receptor coactivator 1 0.0000556 8 6 2 Down
IGF1 Insulin-like growth factor 1 (somatomedin C) 0.00081239 8 2 6 Up
ITGA6 Integrin, α 6 0.00008649 8 5 3 Up
RPS14 Ribosomal protein S14 0.00000185 8 4 4 Up
RHOBTB1 Rho-related BTB domain containing 1 0.00038457 8 7 1 Down
RFC4 Replication factor C (activator 1) 4, 37 kDa 0.00023013 8 6 2 Up
KNTC1 Kinetochore associated 1 0 8 4 4 Up
CENPT Centromere protein T 0 8 0 8 Up
RUVBL2 RuvB-like 2 (E. coli) 0 8 8 0 Up
IL2RA Interleukin 2 receptor, α 0.0002709 8 2 6 Up
MAD1L1 MAD1 mitotic arrest deficient-like 1 (yeast) 0 8 5 3 Up
PLCE1 Phospholipase C, epsilon 1 0 8 8 0 Down
RASGRF2 Ras protein-specific guanine nucleotide-releasing factor 2 0.0002085 7 5 2 Up
FGF7 Fibroblast growth factor 7 (keratinocyte growth factor) 0.00004633 7 2 5 Up
SIX5 SIX homeobox 5 1 7 Up
SMC1B Structural maintenance of chromosomes 1B 0 7 7 0 Up
KDM1A Lysine (K)-specific demethylase 1 0.0001058 7 5 2 Up
CD3E CD3e molecule, epsilon (CD3-TCR complex) 0 7 0 7 Up
PDGFA Platelet-derived growth factor α polypeptide 0.0009675 7 4 3 Down
COL4A4 Collagen, type IV, α 4 0 7 0 7 Up
RAD51 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) 0 7 7 0 Up
BCL2 B-cell CLL/lymphoma 2 0 7 0 7 Up
SMG7 Smg-7 homolog, nonsense mediated mRNA decay factor (C. elegans) 0 7 7 0 Up
FGF5 Fibroblast growth factor 5 0.00007058 7 2 5 Up
OIP5 Opa interacting protein 5 0 7 7 0 Up
RPL14 Ribosomal protein L14 0 7 2 5 Up
SNRPA Small nuclear ribonucleoprotein polypeptide A 0 7 7 0 Up
COL17A1 Collagen, type XVII, α 1 0.00126029 7 1 6 Up
FGF4 Fibroblast growth factor 4 (heparin secretory transforming protein 1, Kaposi sarcoma oncogene) 0 6 0 6 Up
LIMS1 LIM and senescent cell antigen-like domains 1 0 6 6 0 Down
ITGBL1 Integrin, β-like 1 (with EGF-like repeat domains) 0 6 5 1 Up
COL12A1 Collagen, type XII, α 1 0 6 0 6 Up
RBL1 Retinoblastoma-like 1 (p107) 0.00010657 6 5 1 Up
CBX5 Chromobox homolog 5 (HP1 α homolog, Drosophila) 0.00021578 6 1 5 Up
PRKAR2B Protein kinase, cAMP-dependent, regulatory, type II, β 0 6 6 0 Down
SF3B3 Splicing factor 3b, subunit 3, 130 kDa 0.0001529 6 2 4 Up
AP2A2 Adaptor-related protein complex 2, α 2 subunit 0 6 0 6 Up
IGLV1-44 Immunoglobulin lambda variable 1–44 0.00012974 6 1 5 Up
CDK9 Cyclin-dependent kinase 9 0 6 0 6 Up
CSNK2A1 Casein kinase 2, α 1 polypeptide 0.00045515 6 1 5 Up
PELP1 Proline, glutamic acid and leucine rich protein 1 0.00034009 5 4 1 Up
TRAF1 TNF receptor-associated factor 1 0 5 5 0 Up
VIM Vimentin 0 5 5 0 Down
CRTAP Cartilage associated protein 0.00468901 5 3 2 Up
NBN Nibrin 0.00107495 5 2 3 Down
CACNA1A Calcium channel, voltage-dependent, P/Q type, α 1A subunit 0 5 0 5 Up
CIITA Class II, major histocompatibility complex, transactivator 0 5 0 5 Up
IRF1 Interferon regulatory factor 1 0.00002008 5 4 1 Down
FZD1 Frizzled homolog 1 (Drosophila) 0.00061315 5 1 4 Up
SGK1 Serum/glucocorticoid regulated kinase 1 0 5 5 0 Down
APOA1 Apolipoprotein A-I 0.00117688 5 1 4 Up
ZAP70 Zeta-chain (TCR) associated protein kinase 70kDa 0 5 5 0 Up
DYNC2LI1 Dynein, cytoplasmic 2, light intermediate chain 1 0 4 0 4 Up
OSBPL1A Oxysterol binding protein-like 1A 0 4 4 0 Up
RFC3 Replication factor C (activator 1) 3, 38kDa 0.00014364 4 2 2 Up
SERPINH1 Serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1) 0 4 4 0 Up
HNRNPM Recombinant Heterogeneous nuclear ribonucleoprotein M 0.00003243 4 1 3 Up
PIK3C3 Phosphoinositide-3-kinase, class 3 0.00103422 4 1 3 Down
PRKAR1A Protein kinase, cAMP-dependent, regulatory, type I, α (tissue specific extinguisher 1) 0.00000463 4 3 1 Down
AARS Alanyl-tRNA synthetase 0 4 0 4 Up
FZD8 Frizzled homolog 8 (Drosophila) 0 4 0 4 Up
MYO1C Myosin IC 0.00003707 4 1 3 Up
RAB11A RAB11A, member RAS oncogene family 0.00047261 4 3 1 Down
HLA-DOA Major histocompatibility complex, class II, DO α 0.00003707 4 3 1 Up
IGF2 Insulin-like growth factor 2 (somatomedin A) 0.00076297 4 2 2 Up
LDLR Low density lipoprotein receptor (familial hypercholesterolemia) 0.00007105 4 2 2 Up
ENO1 Enolase 1, (α) 0.00003398 4 2 2 Up
ZNF280A Zinc finger protein 280A 0 3 3 0 Up
ARHGAP22 Rho GTPase activating protein 22 0 3 0 3 Up
DDB1 Damage-specific DNA binding protein 1, 127kDa 0 3 0 3 Up
ERCC8 Excision repair cross-complementing rodent repair deficiency, complementation groUp 8 0.0000139 3 1 2 Up
VDR Vitamin D (1,25-dihydroxyvitamin D3) receptor 0 3 3 0 Down
POLD2 Polymerase (DNA directed), delta 2, regulatory subunit 50kDa 0.00012047 3 1 2 Up
CACNB2 Calcium channel, voltage-dependent, β 2 subunit 0 3 1 2 Down
PTCH1 Patched homolog 1 (Drosophila) 0 3 3 0 Up
SPP1 Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) 0 3 3 0 Up
KIF5B Kinesin family member 5B 0.00000927 3 1 2 Down
ARAP3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 0 3 0 3 Down
SKI V-ski sarcoma viral oncogene homolog (avian) 0.00040774 3 2 1 Up
EPS15L1 Epidermal growth factor receptor pathway substrate 15-like 1 0.0000278 3 2 1 Down
FKBP1A FK506 binding protein 1A, 12kDa 0.00009267 3 1 2 Down
RPS6KA4 Ribosomal protein S6 kinase, 90kDa, polypeptide 4 0 3 3 0 Up
BID BH3 interacting domain death agonist 0.00000927 3 1 2 Down
GRIN2A Glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.0000556 3 1 2 Down
NEFL Neurofilament, light polypeptide 68kDa 0.00001853 3 1 2 Up
ANK2 Ankyrin 2, neuronal 0 3 0 3 Up
TIMELESS Timeless homolog (Drosophila) 0 3 3 0 Up
SND1 Staphylococcal nuclease and tudor domain containing 1 0 3 3 0 Up
RPS6KA5 Ribosomal protein S6 kinase, 90kDa, polypeptide 5 0.00006487 3 2 1 Down
RPS6KA2 Ribosomal protein S6 kinase, 90kDa, polypeptide 2 0 3 3 0 Up
RRM2 Ribonucleotide reductase M2 polypeptide 0.00009267 3 2 1 Down
RRM2B Ribonucleotide reductase M2 B (TP53 inducible) 0 3 3 0 Down
GPR4 G protein-coUpled receptor 4 0 3 3 0 Up
WIPF2 WAS/WASL interacting protein family, member 2 0 3 3 0 Down
CFLAR CASP8 and FADD-like apoptosis regulator 0.00104252 3 1 2 Down
ELAVL1 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) 0 3 1 2 Up
IKBKE Inhibitor of κ light polypeptide gene enhancer in B-cells, kinase epsilon 0.00011429 3 1 2 Up
ERBB2IP Erbb2 interacting protein 0.00003707 3 2 1 Down
PAX5 Paired box 5 0.00012371 3 2 1 Up
TACR1 Tachykinin receptor 1 0 3 3 0 Down
MCF2L MCF.2 cell line derived transforming sequence-like 0 3 0 3 Up
NRP2 Neuropilin 2 0.00045407 3 2 1 Up
XAB2 XPA binding protein 2 0 3 3 0 Up
WWOX WW domain containing oxidoreductase 0 3 3 0 Up
TANK TRAF family member-associated NFKB activator 0.00001853 3 2 1 Down
AVPR1A Arginine vasopressin receptor 1A 0 3 0 3 Down
NCKIPSD NCK interacting protein with SH3 domain 0 3 2 1 Up
NEK6 NIMA (never in mitosis gene a)-related kinase 6 0.00010116 3 1 2 Up
CDK19 cyclin-dependent kinase 19 0 3 0 3 Down
B3GALT6 UDP-Gal:βGal β 1,3-galactosyltransferase polypeptide 6 0 2 0 2 Up
NFAT5 Nuclear factor of activated T-cells 5, tonicity-responsive 0 2 2 0 Down
HS2ST1 Heparan sulfate 2-O-sulfotransferase 1 0.00042627 2 1 1 Up
ARHGAP18 Rho GTPase activating protein 18 0 2 0 2 Down
TACC1 Transforming, acidic coiled-coil containing protein 1 0 2 2 0 Up
SNX17 Sorting nexin 17 0.00003398 2 1 1 Up
TPD52L1 Tumor protein D52-like 1 1 2 Up
ALDOC Aldolase C, fructose-bisphosphate 0 2 0 2 Up
FGFBP1 Fibroblast growth factor binding protein 1 0 2 2 0 Up
GRIK1 Glutamate receptor, ionotropic, kainate 1 0 2 0 2 Up
PTGER4 Prostaglandin E receptor 4 (subtype EP4) 0 2 2 0 Down
TXNRD2 Thioredoxin reductase 2 0 2 2 0 Up
FOXL1 Forkhead box L1 0 2 1 1 Up
MXD1 MAX dimerization protein 1 0 2 1 1 Down
TLE2 Transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila) 0 2 2 0 Up
NRCAM Neuronal cell adhesion molecule 0.00001853 2 1 1 Up
KCNAB1 Potassium voltage-gated channel, shaker-related subfamily, β member 1 1 2 Up
UBA5 Ubiquitin-activating enzyme E1-domain containing 1 0 2 0 2 Up
TCF7 Transcription factor 7 (T-cell specific, HMG-box) 0.00037994 2 1 1 Up
WDR77 WD repeat domain 77 0 2 2 0 Up
KIF23 Kinesin family member 23 0 2 1 1 Down
CHRNA1 Cholinergic receptor, nicotinic, α 1 (muscle) 0 2 0 2 Up
AQP2 Aquaporin 2 (collecting duct) 0 2 0 2 Up
MAK Male germ cell-associated kinase 0.00000927 2 1 1 Down
SFRP4 Secreted frizzled-related protein 4 0 2 2 0 Up
TAGAP T-cell activation GTPase activating protein 0 2 2 0 Down
DPYSL5 Dihydropyrimidinase-like 5 1 2 Up
CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein-39) 0 2 0 2 Up
CEP290 Centrosomal protein 290kDa 0 2 0 2 Up
MYH11 Myosin, heavy chain 11, smooth muscle 0.00000927 2 1 1 Up
ZNF341 Zinc finger protein 341 0 2 2 0 Up
DES Desmin 0 2 0 2 Up
NDST1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 0 2 2 0 Down
SLC8A1 Solute carrier family 8 (sodium/calcium exchanger), member 1 0.00000927 2 1 1 Down
PAPPA Pregnancy-associated plasma protein A, pappalysin 1 0 2 2 0 Up
ITPR3 Inositol 1,4,5-triphosphate receptor, type 3 0.00000927 2 1 1 Up
GMFB Glia maturation factor, β 0.00015136 2 1 1 Down
SLC25A4 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 0 2 2 0 Up
CTNND2 Catenin (cadherin-associated protein), delta 2 (neural 0 2 0 2 Up
plakophilin-related arm-repeat protein)
ADAM12 ADAM metallopeptidase domain 12 (meltrin α) 0 2 0 2 Up
IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) 0 2 2 0 Up
IGFBP6 Insulin-like growth factor binding protein 6 0 2 2 0 Up
GTF3C2 General transcription factor IIIC, polypeptide 2, β 110kDa 0 2 1 1 Up
LZTS1 Leucine zipper, putative tumor sUppressor 1 0 2 2 0 Up
GSTO2 Glutathione S-transferase omega 2 0.66666667 2 Up
NPAS2 Neuronal PAS domain protein 2 0 2 2 0 Up
ARHGAP26 Rho GTPase activating protein 26 0 2 0 2 Down
DAB2 Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 0 2 0 2 Down
EIF4E2 Eukaryotic translation initiation factor 4E family member 2 1 2 Up
RPTOR Regulatory associated protein of MTOR, complex 1 0 2 2 0 Up
RASAL2 RAS protein activator like 2 0 2 2 0 Up
FGF14 Fibroblast growth factor 14 0 2 0 2 Up
GXYLT2 Glucoside xylosyltransferase 2 0.00042627 2 1 1 Up
BIN1 Bridging integrator 1 0.00114908 2 1 1 Up
PSEN2 Presenilin 2 (Alzheimer disease 4) 0 2 2 0 Up
RGS18 Regulator of G-protein signaling 18 0 2 2 0 Down
PPM1A Protein phosphatase 1A (formerly 2C), magnesium-dependent α 0.00007413 2 1 1 Down
KIRREL Kin of IRRE like (Drosophila) 0 2 0 2 Up
CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 0.66666667 2 Up
BCL10 B-cell CLL/lymphoma 10 0 2 0 2 Down
ICOS Inducible T-cell co-stimulator 0 2 0 2 Up
HTR1B 5-hydroxytryptamine (serotonin) receptor 1B 0 2 1 1 Up
HTR1D 5-hydroxytryptamine (serotonin) receptor 1D 0 2 2 0 Up
MAF V-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 0 2 2 0 Up
SUPT3H SUppressor of Ty 3 homolog (S. cerevisiae) 0 2 2 0 Up
CHAD Chondroadherin 0 2 0 2 Up
CAD Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase 0 1 Up
CTPS2 CTP synthase II 0 1 Up
PDCD11 Programmed cell death 11 0 1 Up
RBM28 RNA binding motif protein 28 0 1 Up
EIF5A Eukaryotic translation initiation factor 5A 0 1 0 1 Up
CPD Carboxypeptidase D 0 1 Up
DPP4 Dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2) 0 1 1 0 Up
NCALD Neurocalcin delta 0 1 1 0 Down
ZNF169 Zinc finger protein 169 0 1 Up
GABARAPL1 GABA(A) receptor-associated protein like 1 0 1 Down
TECPR2 Tectonin β-propeller repeat containing 2 0 1 Down
PPRC1 Peroxisome proliferator-activated receptor γ, coactivator-related 1 0 1 Up
GPSM1 G-protein signaling modulator 1 (AGS3-like, C. elegans) 0 1 1 0 Up
MRPL14 Mitochondrial ribosomal protein L14 0 1 Up
MRPL4 Mitochondrial ribosomal protein L4 0 1 Up
TNRC6A Trinucleotide repeat containing 6A 0 1 1 0 Up
RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 2 0 1 1 0 Down
KCNA1 Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) 0 1 Up
PAFAH1B3 Platelet-activating factor acetylhydrolase, isoform Ib, γ subunit 29kDa 0 1 1 0 Up
AIRE Autoimmune regulator 0 1 0 1 Up
P2RY13 Purinergic receptor P2Y, G-protein coUpled, 13 0 1 1 0 Down
GATAD2A GATA zinc finger domain containing 2A 0 1 0 1 Up
BAG6 BCL2-associated athanogene 6 0 1 0 1 Up
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 0 1 1 0 Up
BZW2 Basic leucine zipper and W2 domains 2 0 1 0 1 Up
CHRNB2 Cholinergic receptor, nicotinic, β 2 (neuronal) 0 1 1 0 Up
SARS Seryl-tRNA synthetase 0 1 1 0 Up
RYBP RING1 and YY1 binding protein 0 1 1 0 Down
ADCY5 Adenylate cyclase 5 0 1 0 1 Up
GALT Galactose-1-phosphate uridylyltransferase 0 1 0 1 Up
STON2 Stonin 2 0 1 1 0 Down
DGKA Diacylglycerol kinase, α 80kDa 0 1 0 1 Up
PLXNA4 Plexin A4 0 1 Up
MYLK Myosin, light chain kinase 0 1 1 0 Down
MYF6 Myogenic factor 6 (herculin) 0 1 1 0 Up
MDN1 MDN1, midasin homolog (yeast) 0 1 1 0 Up
AMN Amnionless homolog (mouse) 0 1 0 1 Up
DOCK9 Dedicator of cytokinesis 9 0 1 0 1 Up
PDK2 Pyruvate dehydrogenase kinase, isozyme 2 0 1 0 1 Up
MOB1B MOB kinase activator 1B 0 1 Down
SAV1 Salvador homolog 1 (Drosophila) 0 1 Up
PIK3R6 phosphoinositide-3-kinase, regulatory subunit 6 0 1 1 0 Up
IMPAD1 Inositol monophosphatase domain containing 1 0 1 0 1 Up
NR2F2 Nuclear receptor subfamily 2, groUp F, member 2 0 1 1 0 Up
JMJD1C Jumonji domain containing 1C 0 1 1 0 Down
IPO5 Importin 5 0 1 1 0 Up
PPIL2 Peptidylprolyl isomerase (cyclophilin)-like 2 0 1 1 0 Up
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 0 1 Up
ELP2 Elongation protein 2 homolog (S. cerevisiae) 0 1 Up
IKBKAP Inhibitor of κ light polypeptide gene enhancer in B-cells, kinase complex-associated protein 0 1 Down
BRD9 Bromodomain containing 9 0 1 0 1 Up
RAMP3 Receptor (G protein-coUpled) activity modifying protein 3 0 1 1 0 Up
NAP1L4 Nucleosome assembly protein 1-like 4 0 1 1 0 Up
NTRK3 Neurotrophic tyrosine kinase, receptor, type 3 0 1 1 0 Up
CXCL5 Chemokine (C-X-C motif) ligand 5 0 1 0 1 Down
NDRG2 NDRG family member 2 0 1 1 0 Up
SEMA3F Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F 0 1 1 0 Up
RUNX2 Runt-related transcription factor 2 0 1 0 1 Up
MPP2 Membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) 0 1 1 0 Up
SLC40A1 Solute carrier family 40 (iron-regulated transporter), member 1 0 1 1 0 Down
SREK1 Splicing regulatory glutamine/lysine-rich protein 1 0 1 1 0 Up
ING2 Inhibitor of growth family, member 2 0 1 1 0 Down
AKIRIN2 Akirin 2 0 1 Down
CDH6 Cadherin 6, type 2, K-cadherin (fetal kidney) 0 1 Up
CDH7 Cadherin 7, type 2 0 1 Up
KCNC1 Potassium voltage-gated channel, Shaw-related subfamily, member 1 0 1 Up
TMEM173 Transmembrane protein 173 0 1 1 0 Up
ZNF775 Zinc finger protein 775 0 1 1 0 Up
DTX3 Deltex 3 homolog (Drosophila) 0 1 0 1 Up
EIF4G2 Eukaryotic translation initiation factor 4 γ, 2 0 1 Up
ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 0 1 1 0 Down
ZNF133 Zinc finger protein 133 0 1 Up
SPAG9 Sperm associated antigen 9 0 1 1 0 Down
SLC4A4 Solute carrier family 4, sodium bicarbonate cotransporter, member 4 0 1 Up
SLC4A7 Solute carrier family 4, sodium bicarbonate cotransporter, member 7 0 1 Up
MYBBP1A MYB binding protein (P160) 1a 0 1 1 0 Up
WARS2 Tryptophanyl tRNA synthetase 2, mitochondrial 0 1 1 0 Up
KCNJ2 Potassium inwardly-rectifying channel, subfamily J, member 2 0 1 1 0 Down
DGKH Diacylglycerol kinase, eta 0 1 0 1 Up
ANGPTL4 Angiopoietin-like 4 0 1 0 1 Up
MAPKAP1 Mitogen-activated protein kinase associated protein 1 0 1 0 1 Up
RAB11FIP1 RAB11 family interacting protein 1 (class I) 0 1 1 0 Down
IHH Indian hedgehog homolog (Drosophila) 0 1 0 1 Up
SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 1 0 1 1 0 Up
ADAM9 ADAM metallopeptidase domain 9 (meltrin γ) 0 1 0 1 Up
ST3GAL6 ST3 β-galactoside α-2,3-sialyltransferase 6 0 1 1 0 Down
ST3GAL3 ST3 β-galactoside α-2,3-sialyltransferase 3 0 1 1 0 Up
PIGB Phosphatidylinositol glycan anchor biosynthesis, class B 0 1 1 0 Down
SLC7A8 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 0 1 1 0 Up
AHI1 Abelson helper integration site 1 0 1 0 1 Up
DDR2 Discoidin domain receptor family, member 2 0 1 0 1 Up
MC3R Melanocortin 3 receptor 0 1 1 0 Up
TXN2 Thioredoxin 2 0 1 0 1 Up
PROX1 Prospero homeobox 1 0 1 1 0 Up
NABP1 Nucleic acid binding protein 1 0 1 0 1 Down
TUBB1 Tubulin, β 1 0 1 1 0 Down
PLCL2 Phospholipase C-like 2 0 1 1 0 Up
CARD14 Caspase recruitment domain family, member 14 0 1 1 0 Up
JDP2 Jun dimerization protein 2 0 1 1 0 Down
ZNF77 Zinc finger protein 77 0 1 1 0 Up
ZBTB25 Zinc finger and BTB domain containing 25 0 1 1 0 Up
AP4E1 Adaptor-related protein complex 4, epsilon 1 subunit 0 1 Up
ADAM15 ADAM metallopeptidase domain 15 0 1 0 1 Up
DNAH1 Dynein, axonemal, heavy chain 1 0 1 1 0 Up
FARSB Phenylalanyl-tRNA synthetase, β subunit 0 1 1 0 Up
INSL3 Insulin-like 3 (Leydig cell) 0 1 1 0 Up
TAS2R45 Taste receptor, type 2, member 45 0 1 1 0 Down
PRL Prolactin 0 1 1 0 Up
ATP2A1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 0 1 0 1 Up
EYA4 Eyes absent homolog 4 (Drosophila) 0 1 Up
BMP6 Bone morphogenetic protein 6 0 1 0 1 Down
MKNK1 MAP kinase interacting serine/threonine kinase 1 0 1 Down
TCEA2 Transcription elongation factor A (SII), 2 0 1 1 0 Up
L3MBTL1 l (3) mbt-like 1 0 1 1 0 Up
ASAP2 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 0 1 0 1 Down
ZFYVE16 Zinc finger, FYVE domain containing 16 0 1 1 0 Down
HEXIM1 Hexamethylene bis-acetamide inducible 1 0 1 1 0 Up
NEK3 NIMA (never in mitosis gene a)-related kinase 3 0 1 1 0 Up
DDX56 DEAD (Asp-Glu-Ala-Asp) box polypeptide 56 0 1 Up
RPF1 Ribosome production factor 1 homolog 0 1 Up
STX3 Syntaxin 3 0 1 Down
STX7 Syntaxin 7 0 1 Down
GATM Glycine amidinotransferase (L-arginine:glycine amidinotransferase) 0 1 Up
ELL Elongation factor RNA polymerase II 0 1 1 0 Down
EZH1 Enhancer of zeste homolog 1 (Drosophila) 0 1 Up
JARID2 Jumonji, AT rich interactive domain 2 0 1 Down
NKD2 Naked cuticle homolog 2 (Drosophila) 0 1 1 0 Up
ZNF569 Zinc finger protein 569 0 1 Up
C1QC Complement component 1, q subcomponent, C chain 0 1 0 1 Up
DPYS Dihydropyrimidinase 0 1 Up
LZTR1 Leucine-zipper-like transcription regulator 1 0 1 0 1 Up
VWA1 Von Willebrand factor A domain containing 1 0 1 1 0 Up
PEX14 Peroxisomal biogenesis factor 14 0 1 Up
PEX3 Peroxisomal biogenesis factor 3 0 1 Up
PLAU Plasminogen activator, urokinase 0 1 1 0 Up
PLAGL1 Pleiomorphic adenoma gene-like 1 0 1 1 0 Down
LDLRAP1 Low density lipoprotein receptor adaptor protein 1 0 1 1 0 Up
NPAS4 Neuronal PAS domain protein 4 0 1 1 0 Up
BAZ1A Bromodomain adjacent to zinc finger domain, 1A 0 1 0 1 Down
RQCD1 RCD1 required for cell differentiation 1 homolog (S. pombe) 0 1 1 0 Up
ZNF337 Zinc finger protein 337 0 1 up

Up, upregulated; Down, downregulated.